Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
CNR Institutional Research Information System
Background We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-
dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15-20% of cases of
life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain
to be identified in ~ 80% of cases.
Methods We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with
life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the
928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded.
Results No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk
variants was TLR7, with an OR of 27.68 (95%CI 1.5-528.7, P = 1.1 × 10-
4) for biochemically loss-of-function (bLOF)
variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved
in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3-8.2], P = 2.1 × 10-
4). This enrichment was further
strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model
(OR = 19.65[95%CI 2.1-2635.4], P = 3.4 × 10-
3), and (2) considering as pLOF branchpoint variants with potentially
strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3-8.4], P = 7.7 × 10-
8). Finally, the patients with pLOF/
bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients
(56.0 [17.3] years; P = 1.68 × 10-
5).
Conclusions Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening
COVID-19, particularly with recessive inheritance, in patients under 60 years old.
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
Members of COVID Clinicians Jorge Abad;Giulia Accordino;CristianAchille;Sergio AguileraAlbesa;Aina AguilóCucurull;Alessandro Aiuti;EsraAkyuz Özkan;Ilad Alavi Darazam;Jonathan Antonio Roblero Albisures;JuanC Aldave;Miquel Alfonso Ramos;Taj Ali Khan;Anna Aliberti;SeyedAlireza Nadji;Gulsum Alkan;Suzan A AlKhater;Jerome AllardetServent;Luis M Allende;Rebeca AlonsoArias;Mohammed S Alshahrani;LaiaAlsina;MarieAlexandra Alyanakian;Blanca Amador Borrero;ZahirAmoura;Arnau Antolí;Romain Arrestier;Mélodie Aubart;TeresaAuguet;Iryna Avramenko;Gökhan Aytekin;Axelle Azot;SeiamakBahram;Fanny Bajolle;Fausto Baldanti;Aurélie Baldolli;Maite Ballester;Hagit Baris Feldman;Benoit Barrou;Federica Barzaghi;Sabrina Basso;Gulsum Iclal Bayhan;Alexandre Belot;Liliana Bezrodnik;AgurtzaneBilbao;Geraldine BlanchardRohner;Ignacio Blanco;Adeline Blandinières;Daniel BlázquezGamero;Alexandre Bleibtreu;MarketaBloomfield;Mireia BolivarPrados;Anastasiia Bondarenko;AlessandroBorghesi;Raphael Borie;Elisabeth BotdhloNevers;Ahmed A Bousfiha;Aurore Bousquet;David Boutolleau;Claire Bouvattier;OksanaBoyarchuk;Juliette Bravais;M Luisa Briones;MarieEve Brunner;RaffaeleBruno;Maria Rita P Bueno;Huda Bukhari;Jacinta Bustamante;Juan JoséCáceres Agra;Ruggero Capra;Raphael Carapito;Maria Carrabba;Giorgio Casari;Carlos Casasnovas;Marion Caseris;Irene Cassaniti;MartinCastelle;Francesco Castelli;Martín Castillo de Vera;Mateus V Castro;Emilie Catherinot;Jale Bengi Celik;Alessandro Ceschi;MartinChalumeau;Bruno Charbit;Matthew P Cheng;Père Clavé;BonaventuraClotet;Anna Codina;Yves Cohen;Roger Colobran;Cloé Comarmond;Alain Combes;Patrizia Comoli;Angelo G Corsico;Betul Sozeri;TanerCokuner;Aleksandar Cvetkovski;Cyril Cyrus;David Dalmau;FrançoisDanion;David Ross Darley;Vincent Das;Nicolas Dauby;StéphaneDauger;Paul De Munter;Loic de Pontual;Amin Dehban;GeoffroyDelplancq;Alexandre Demoule;Isabelle Desguerre;Antonio DiSabatino;JeanLuc Diehl;Stephanie Dobbelaere;Elena DomínguezGarrido;Clément Dubost;Olov Ekwall;efika Elmas Bozdemir;Giovanna Fabio;Laurence Faivre;Antonin Falck;Muriel Fartoukh;Morgane Faure;Miguel Fernandez Arquero;Ricard Ferrer;JoseFerreres;Carlos Flores;Bruno Francois;Victoria Fumadó;Kitty S CFung;Francesca Fusco;Alenka Gagro;Blanca Garcia Solis;PierreGarçon;Pascale Gaussem;Zeynep Gayretli;Juana GilHerrera;Laurent Gilardin;Audrey Giraud Gatineau;Mònica GironaAlarcón;Karen Alejandra Cifuentes Godínez;JeanChristophe Goffard;NachoGonzales;Luis I GonzalezGranado;Rafaela GonzálezMontelongo;Antoine Guerder;Belgin Gulhan;Victor Daniel Gumucio;Leif GunnarHanitsch;Jan Gunst;Marta Gut;Jérôme Hadjadj;FilomeenHaerynck;Rabih Halwani;Lennart Hammarström;Selda Hancerli;Tetyana Hariyan;Nevin Hatipoglu;Deniz Heppekcan;Elisa HernandezBrito;Poki Ho;María Soledad HolandaPeña;Juan P Horcajada;SamiHraiech;Linda Humbert;Ivan F N Hung;Alejandro D Iglesias;Antonio ÍñigoCampos;Matthieu Jamme;María Jesús Arranz;MarieThérèse Jimeno;Iolanda Jordan;Saliha Kank Yuksek;Yalcin BurakKara;Aydn Karahan;Adem Karbuz;Kadriye Kart Yasar;OzgurKasapcopur;Kenichi Kashimada;Sevgi Keles;Yasemin KendirDemirkol;Yasutoshi Kido;Can Kizil;Ahmet Osman Klç;AdamKlocperk;Antonia Koutsoukou;Zbigniew J Król;Hatem Ksouri;PaulKuentz;Arthur M C Kwan;Yat Wah M Kwan;Janette S Y Kwok;JeanChristophe Lagier;David S Y Lam;Vicky Lampropoulou;FannyLanternier;YuLung Lau;Fleur Le Bourgeois;YeeSin Leo;Rafael LeonLopez;Daniel Leung;Michael Levin;Michael Levy;Romain Lévy;ZhiLi;Daniele Lilleri;Edson Jose Adrian Bolanos Lima;Agnes LiMarwa H Elnagdy;Melike Emiroglu;Akifumi Endo;Emine HafizeErdeniz;Selma Erol Aytekin;Maria Pilar Etxart Lasa;Romain EuvrardMatilde Valeria Ursini
2023
Abstract
Background We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-
dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15-20% of cases of
life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain
to be identified in ~ 80% of cases.
Methods We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with
life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the
928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded.
Results No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk
variants was TLR7, with an OR of 27.68 (95%CI 1.5-528.7, P = 1.1 × 10-
4) for biochemically loss-of-function (bLOF)
variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved
in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3-8.2], P = 2.1 × 10-
4). This enrichment was further
strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model
(OR = 19.65[95%CI 2.1-2635.4], P = 3.4 × 10-
3), and (2) considering as pLOF branchpoint variants with potentially
strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3-8.4], P = 7.7 × 10-
8). Finally, the patients with pLOF/
bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients
(56.0 [17.3] years; P = 1.68 × 10-
5).
Conclusions Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening
COVID-19, particularly with recessive inheritance, in patients under 60 years old.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/436547
Citazioni
ND
ND
ND
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall'Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l'Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.